Hello [NAME OF REPRESENTATIVE],

I appreciate you taking the time to speak with me about pulmonary arterial hypertension and the importance of publicly funded access to sotatercept (Winrevair™) in this province to allow for the best possible outcomes for those living with this disease.

Now that Canada’s Drug Agency has recommended that sotatercept be publicly funded we hope swift and favourable negotiations through the pan-Canadian Pharmaceutical Alliance (pCPA) will enable people to access to this therapy soon in [NAME OF PROVINCE].

I also want to thank you for your willingness to reach out to the Minister of Health on this important issue on behalf of people living with pulmonary arterial hypertension. Please find attached a draft letter, which you are welcome to customize and send to the Minister. I would appreciate it if you could copy me on the letter when you send it.

In the meantime, if you have any questions, please feel free to reach out to me or to the Pulmonary Hypertension Association of Canada directly at [info@phacanada.ca](mailto:info@phacanada.ca).

Sincerely,

[NAME]